Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
Adult
Blood Glucose
Blood Glucose Self-Monitoring
Body Mass Index
Diabetes Mellitus, Type 1
/ drug therapy
Double-Blind Method
Drug Therapy, Combination
Europe
Glycated Hemoglobin
/ analysis
Glycosides
Humans
Hypoglycemic Agents
/ adverse effects
Insulin
/ therapeutic use
Sodium
Sodium-Glucose Transporter 2 Inhibitors
/ adverse effects
insulin therapy, SGLT2 inhibitor, type 1 diabetes, weight control, glycaemic control
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
09
07
2020
revised:
23
11
2020
accepted:
24
11
2020
pubmed:
9
12
2020
medline:
9
7
2021
entrez:
8
12
2020
Statut:
ppublish
Résumé
Sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1/SGLT2 inhibitor, is currently approved in Europe as an adjunct to optimal insulin therapy in adults with type 1 diabetes (T1D) and a body mass index (BMI) ≥ 27 kg/m
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Glycosides
0
Hypoglycemic Agents
0
Insulin
0
Sodium-Glucose Transporter 2 Inhibitors
0
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
6B4ZBS263Y
Sodium
9NEZ333N27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
854-860Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Fellinger P, Fuchs D, Wolf P, et al. Overweight and obesity in type 1 diabetes equal those of the general population. Wien Klin Wochenschr. 2019;131(3-4):55-60.
Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72.
Purnell JQ, Zinman B, Brunzell JD. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation. 2013;127(2):180-187.
Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The North American inTandem1 Study. Diabetes Care. 2018;41(9):1970-1980.
Danne T, Cariou B, Banks P, et al. HbA1c and hypoglycemia reduction at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care. 2018;41(9):1981-1990.
Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377:2337-2348.
European Medicines Agency. Zynquista (sotagliflozin). 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/zynquista. Accessed March 10, 2020.
National Institute for Health and Care Excellence. Sotagliflozin with insulin for treating type 1 diabetes. 2020. https://www.nice.org.uk/guidance/ta622/chapter/1-Recommendations. Accessed March 10, 2020.
National Institute for Health and Care Excellence. Dapagliflozin with insulin for treating type 1 diabetes. 2020. https://www.nice.org.uk/guidance/ta597/chapter/1-Recommendations. Accessed March 10, 2020.
European Medicines Agency. Forxiga (dapagliflozin). 2020; https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga. Accessed March 10, 2020.
Danne T, Cariou B, Buse JB, et al. Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the inTandem Program. Diabetes Care. 2019;42(5):919-930.
Misra S, Oliver NS. Diabetic ketoacidosis in adults. BMJ. 2015;351:h5660.
Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42(6):1147-1154.
Peters AL, McGuire DK, Danne T, et al. Diabetic ketoacidosis and related events with sotagliflozin added to insulin in adults with type 1 diabetes: a pooled analysis of the inTandem 1 and 2 studies. Diabetes Care. 2020;43(11):2713-2720.
Mathieu C, Dandona P, Birkenfeld AL, et al. Benefit:risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and BMI ≥27 kg/m2. Diabetes Obes Metab. 2020;22(11):2151-2160.
Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-493.